Dicerna Pharmaceuticals Logo

Email this page: News Release

Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies

For security reasons, registration is required before you can use this feature.
* Indicates required field